Viewing Study NCT05061134

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:19 AM
Ignite Modification Date: 2026-02-20 @ 6:39 PM
Study NCT ID: NCT05061134
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-31
First Post: 2021-09-22
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Unresectable or Advanced Melanoma View
None Efficacy View
None Safety View